Skip to main content
Erschienen in:

01.05.2005 | Leitthema

Moderne immuntherapeutische Ansätze für die Behandlung von Lungen- und Kopf-Hals-Tumoren

verfasst von: PD Dr. F. Lohr, A. Dietz, A. Hoos

Erschienen in: Die Onkologie | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Zusammenfassung

Multimodale Therapiestrategien, die Chirurgie, Strahlen- und Chemotherapie kombinieren, haben die Behandlungsergebnisse bei Tumoren der Lunge und der Kopf-Hals Region verbessert. Die Ergänzung des Therapiespektrums um weitere Ansätze, die sich in der Wirkungsweise und möglichst durch reduzierte Toxizität von den konventionellen unterscheiden, erscheint jedoch zur Erzielung weiterer Fortschritte notwendig. Eine neue Generation immunologischer passiver (antikörperbasierter) und auch aktiver (Vakzinierungs-) Strategien erscheint aussichtsreich und befindet sich gegenwärtig in der klinischen Prüfung. Die Untersuchung der optimalen zeitlichen Sequenz in Kombination mit den konventionellen Therapieverfahren und die Individualisierung der Therapie auf Basis genomischer/proteomischer Daten muss die klinische Integration begleiten.
Literatur
1.
Zurück zum Zitat 6. Internationale Konferenz für Kopf-Hals Tumoren. Washington DC, 2004 6. Internationale Konferenz für Kopf-Hals Tumoren. Washington DC, 2004
2.
Zurück zum Zitat Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351–360 Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351–360
3.
Zurück zum Zitat Baumann M, Krause M (2004) Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 72:257–266 Baumann M, Krause M (2004) Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 72:257–266
4.
Zurück zum Zitat Berinstein N (2003) Overview of therapeutic vaccination approaches for cancer. Semin Oncol 30:1–8 Berinstein N (2003) Overview of therapeutic vaccination approaches for cancer. Semin Oncol 30:1–8
5.
Zurück zum Zitat Bonner JA, Harari PM, Giralt J, Azarnia N, Cohen RB, Raben D, Jones C, Kies MS, Baselga J, Ang KK (2004) Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol (Meeting Abstracts) 22:5507 Bonner JA, Harari PM, Giralt J, Azarnia N, Cohen RB, Raben D, Jones C, Kies MS, Baselga J, Ang KK (2004) Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol (Meeting Abstracts) 22:5507
6.
Zurück zum Zitat Borjesson PK, Postema EJ, Roos JC, Colnot DR, Marres HA, van Schie MH, Stehle G, de Bree R, Snow GB, Oyen WJ, van Dongen GA (2003) Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 9:3961S–3972S Borjesson PK, Postema EJ, Roos JC, Colnot DR, Marres HA, van Schie MH, Stehle G, de Bree R, Snow GB, Oyen WJ, van Dongen GA (2003) Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 9:3961S–3972S
7.
Zurück zum Zitat Bunn PA Jr (1999) Immune therapy for lung cancer: are we getting closer? Am J Respir Cell Mol Biol 21:10–12 Bunn PA Jr (1999) Immune therapy for lung cancer: are we getting closer? Am J Respir Cell Mol Biol 21:10–12
8.
Zurück zum Zitat Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE (2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980–1987 Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE (2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980–1987
9.
Zurück zum Zitat Cohen S, Carpenter G, King L Jr (1980) Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 255:4834–4842 Cohen S, Carpenter G, King L Jr (1980) Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 255:4834–4842
10.
Zurück zum Zitat Cowley GP, Smith JA, Gusterson BA (1986) Increased EGF receptors on human squamous carcinoma cell lines. Br J Cancer 53:223–229 Cowley GP, Smith JA, Gusterson BA (1986) Increased EGF receptors on human squamous carcinoma cell lines. Br J Cancer 53:223–229
11.
Zurück zum Zitat Crawford J, Sandler AB, Hammond LA, Schiller J, Belani C, Kozloff M, Johnson D, Fleishman A, Lee S, Takeshita K (2004) ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 22:7083 Crawford J, Sandler AB, Hammond LA, Schiller J, Belani C, Kozloff M, Johnson D, Fleishman A, Lee S, Takeshita K (2004) ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 22:7083
12.
Zurück zum Zitat Crombet T, Neninger E, Osorio M, Catala M, Torre A, Leonard I, Garcia B, Gonzalez G, Perez R, Lage A (2004) Vaccination with epidermal growth factor (EGF) for non small cell lung cancer (NSCLC) therapy: Preliminary results from a randomized phase II clinical trial. J Clin Oncol (Meeting Abstracts) 22:2514 Crombet T, Neninger E, Osorio M, Catala M, Torre A, Leonard I, Garcia B, Gonzalez G, Perez R, Lage A (2004) Vaccination with epidermal growth factor (EGF) for non small cell lung cancer (NSCLC) therapy: Preliminary results from a randomized phase II clinical trial. J Clin Oncol (Meeting Abstracts) 22:2514
13.
Zurück zum Zitat Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernandez E, Alvarez D, Torres O, Ramos M, Leonard I, Perez R, Lage A (2004) Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 22:1646–1654 Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernandez E, Alvarez D, Torres O, Ramos M, Leonard I, Perez R, Lage A (2004) Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 22:1646–1654
14.
Zurück zum Zitat Dazzi H, Hasleton PS, Thatcher N, Barnes DM, Wilkes S, Swindell R, Lawson RA (1989) Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. Br J Cancer 59:746–749 Dazzi H, Hasleton PS, Thatcher N, Barnes DM, Wilkes S, Swindell R, Lawson RA (1989) Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. Br J Cancer 59:746–749
15.
Zurück zum Zitat Finkelman FD, Lees A, Birnbaum R, Gause WC, Morris SC (1996) Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J Immunol 157:1406–1414 Finkelman FD, Lees A, Birnbaum R, Gause WC, Morris SC (1996) Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J Immunol 157:1406–1414
16.
Zurück zum Zitat Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, Barton C, Ghahramani P, Hirsh V (2004) Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 15:19–27 Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, Barton C, Ghahramani P, Hirsh V (2004) Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 15:19–27
17.
Zurück zum Zitat Gaudernack G, Buanes T, Meo M, Aamdal S, Brunsvig P, Braathen LR, Kernland K, Gjertsen MK, Eriksen JA, Moller M (2003) Clinical trials of a peptide based vaccine targeting telomerase. Proc Am Soc Clin Oncol (Meeting Abstracts) 22:166 Gaudernack G, Buanes T, Meo M, Aamdal S, Brunsvig P, Braathen LR, Kernland K, Gjertsen MK, Eriksen JA, Moller M (2003) Clinical trials of a peptide based vaccine targeting telomerase. Proc Am Soc Clin Oncol (Meeting Abstracts) 22:166
18.
Zurück zum Zitat Giaccone G, Debruyne C, Felip E, Millward M, D’Addario G, Thiberville L, Rome L, Zatloukal P, Legrand C (2004) Phase III study of BEC2/BCG vaccination in limited disease small cell lung cancer (LD-SCLC) patients, following response to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study). J Clin Oncol (Meeting Abstracts) 22:7020 Giaccone G, Debruyne C, Felip E, Millward M, D’Addario G, Thiberville L, Rome L, Zatloukal P, Legrand C (2004) Phase III study of BEC2/BCG vaccination in limited disease small cell lung cancer (LD-SCLC) patients, following response to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study). J Clin Oncol (Meeting Abstracts) 22:7020
19.
Zurück zum Zitat Gilboa E, Vieweg J (2004) Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199:251–263 Gilboa E, Vieweg J (2004) Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199:251–263
20.
Zurück zum Zitat Gonzalez G, Viada C, Neninger E, Crombet T, Leonard I, Garcia B, Lage A (2004) Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: Analysis of pooled data from three clinical trials. J Clin Oncol (Meeting Abstracts) 22:2548 Gonzalez G, Viada C, Neninger E, Crombet T, Leonard I, Garcia B, Lage A (2004) Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: Analysis of pooled data from three clinical trials. J Clin Oncol (Meeting Abstracts) 22:2548
21.
Zurück zum Zitat Hadden J, Verastegui E, Barrera JL, Kurman M, Meneses A, Zinser JW, de la Garza J, Hadden E (2003) A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck. Int Immunopharmacol 3:1073–1081 Hadden J, Verastegui E, Barrera JL, Kurman M, Meneses A, Zinser JW, de la Garza J, Hadden E (2003) A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck. Int Immunopharmacol 3:1073–1081
22.
Zurück zum Zitat Hege KM, Carbone DP (2003) Lung cancer vaccines and gene therapy. Lung Cancer 41 [Suppl 1]: S103–113 Hege KM, Carbone DP (2003) Lung cancer vaccines and gene therapy. Lung Cancer 41 [Suppl 1]: S103–113
23.
Zurück zum Zitat Helft PR, Schilsky RL, Hoke FJ, Williams D, Kindler HL, Sprague E, DeWitte M, Martino HK, Erickson J, Pandite L, Russo M, Lambert JM, Howard M, Ratain MJ (2004) A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res 10:4363–4368 Helft PR, Schilsky RL, Hoke FJ, Williams D, Kindler HL, Sprague E, DeWitte M, Martino HK, Erickson J, Pandite L, Russo M, Lambert JM, Howard M, Ratain MJ (2004) A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res 10:4363–4368
24.
Zurück zum Zitat Herbst RS, Sandler AB (2004) Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? Oncologist 9 [Suppl 1]:19–26 Herbst RS, Sandler AB (2004) Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? Oncologist 9 [Suppl 1]:19–26
25.
Zurück zum Zitat Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M (2000) Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 161:589–594 Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M (2000) Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 161:589–594
26.
Zurück zum Zitat Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J (2004) Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 22:2808–2815 Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J (2004) Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 22:2808–2815
27.
Zurück zum Zitat Hofheinz RD, al-Batran SE, Hartmann F, Hartung G, Jager D, Renner C, Tanswell P, Kunz U, Amelsberg A, Kuthan H, Stehle G (2003) Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 26:44–48 Hofheinz RD, al-Batran SE, Hartmann F, Hartung G, Jager D, Renner C, Tanswell P, Kunz U, Amelsberg A, Kuthan H, Stehle G (2003) Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 26:44–48
28.
Zurück zum Zitat Hoos A (2004) The promise of Cancer Vaccines. Drug Discovery Develop 13 Hoos A (2004) The promise of Cancer Vaccines. Drug Discovery Develop 13
29.
Zurück zum Zitat Ishioka GY, Disis ML, Morse MA, Cunningham CC, Lenz H-J, Figlin RA, Chesnut RW, Fikes J (2004) A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients. J Clin Oncol (Meeting Abstracts) 22:2525 Ishioka GY, Disis ML, Morse MA, Cunningham CC, Lenz H-J, Figlin RA, Chesnut RW, Fikes J (2004) A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients. J Clin Oncol (Meeting Abstracts) 22:2525
30.
Zurück zum Zitat Korst RJ, Crystal RG (2003) Active, specific immunotherapy for lung cancer: hurdles and strategies using genetic modification. Ann Thorac Surg 76:1319–1326 Korst RJ, Crystal RG (2003) Active, specific immunotherapy for lung cancer: hurdles and strategies using genetic modification. Ann Thorac Surg 76:1319–1326
31.
Zurück zum Zitat Krug LM, Ragupathi G, Hood C, Kris MG, Miller VA, Allen JR, Keding SJ, Danishefsky SJ, Gomez J, Tyson L, Pizzo B, Baez V, Livingston PO (2004) Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin Cancer Res 10:6094–6100 Krug LM, Ragupathi G, Hood C, Kris MG, Miller VA, Allen JR, Keding SJ, Danishefsky SJ, Gomez J, Tyson L, Pizzo B, Baez V, Livingston PO (2004) Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin Cancer Res 10:6094–6100
32.
Zurück zum Zitat Leichman G, Gravenor D, Albert G, Schmalbach T (2004) A TLR9 CpG immunomodulator in combination with chemotherapy as treatment for advanced non-small cell lung cancer (NSCLS), a randomized, controlled phase II study. J Clin Oncol (Meeting Abstracts) 22:7126 Leichman G, Gravenor D, Albert G, Schmalbach T (2004) A TLR9 CpG immunomodulator in combination with chemotherapy as treatment for advanced non-small cell lung cancer (NSCLS), a randomized, controlled phase II study. J Clin Oncol (Meeting Abstracts) 22:7126
33.
Zurück zum Zitat Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P (2004) Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 101 [Suppl 2]:14567–14571 Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P (2004) Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 101 [Suppl 2]:14567–14571
34.
Zurück zum Zitat Loibner H, Eckert H, Eller N, Groiss F, Himmler G, Rosenkaimer F, Salzberg M, Samonigg H, Schuster M, Settaf A (2004) A randomized placebo-controlled phase II study with the cancer vaccine IGN101 in patients with epithelial solid organ tumors (IGN101/2–01). J Clin Oncol (Meeting Abstracts) 22:2619 Loibner H, Eckert H, Eller N, Groiss F, Himmler G, Rosenkaimer F, Salzberg M, Samonigg H, Schuster M, Settaf A (2004) A randomized placebo-controlled phase II study with the cancer vaccine IGN101 in patients with epithelial solid organ tumors (IGN101/2–01). J Clin Oncol (Meeting Abstracts) 22:2619
35.
Zurück zum Zitat Lynch TJ, Lilenbaum R, Bonomi P, Ansari R, Govindan R, Janne PA, Hanna N (2004) A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 22:7084 Lynch TJ, Lilenbaum R, Bonomi P, Ansari R, Govindan R, Janne PA, Hanna N (2004) A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 22:7084
36.
Zurück zum Zitat Mason KA, Neal R, Hunter NR, Ariga H, Krieg AM, Whisnant JK, Milas L (2004) CpG oligodeoxynucleotide (ODN) is a potent enhancer of fractionated radiotherapy. J Clin Oncol (Meeting Abstracts) 22:3113 Mason KA, Neal R, Hunter NR, Ariga H, Krieg AM, Whisnant JK, Milas L (2004) CpG oligodeoxynucleotide (ODN) is a potent enhancer of fractionated radiotherapy. J Clin Oncol (Meeting Abstracts) 22:3113
37.
Zurück zum Zitat Milas L, Mason KA, Ariga H, Hunter N, Neal R, Valdecanas D, Krieg AM, Whisnant JK (2004) CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 64:5074–5077 Milas L, Mason KA, Ariga H, Hunter N, Neal R, Valdecanas D, Krieg AM, Whisnant JK (2004) CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 64:5074–5077
38.
Zurück zum Zitat Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 19:3159–3167 Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 19:3159–3167
39.
Zurück zum Zitat Port Metaanalysis Group (1998) Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 352:257–263 Port Metaanalysis Group (1998) Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 352:257–263
40.
Zurück zum Zitat Ribas A, Butterfield LH, Glaspy JA, Economou JS (2003) Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 21:2415–2432 Ribas A, Butterfield LH, Glaspy JA, Economou JS (2003) Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 21:2415–2432
41.
Zurück zum Zitat Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R, Tartour E, Zhao Y, Bizouarne N, Baudin M, Acres B (2003) Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 5:690–699 Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R, Tartour E, Zhao Y, Bizouarne N, Baudin M, Acres B (2003) Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 5:690–699
42.
Zurück zum Zitat Rosell R, Daniel C, Ramlau R, Szczesna A, Constenla M, Mennecier B, Pfeifer W, Mueser M, Montaner I, Gatzemeier U (2004) Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 22:7012 Rosell R, Daniel C, Ramlau R, Szczesna A, Constenla M, Mennecier B, Pfeifer W, Mueser M, Montaner I, Gatzemeier U (2004) Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 22:7012
43.
Zurück zum Zitat Ross HJ, Rudin CM, Hart LL, Swanson PM, Rarick MU, Figlin RA, Jacobs AD, Miller DM (2004) Randomized phase II study of SGN-15 (CBR96-doxorubicin immunoconjugate) with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 22:7039 Ross HJ, Rudin CM, Hart LL, Swanson PM, Rarick MU, Figlin RA, Jacobs AD, Miller DM (2004) Randomized phase II study of SGN-15 (CBR96-doxorubicin immunoconjugate) with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 22:7039
44.
Zurück zum Zitat Sandler AB, Blumenschein GR, Henderson T, Lee J, Truong M, Kim E, Mass B, Garcia B, Johnson DH, Herbst RS (2004) Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. J Clin Oncol (Meeting Abstracts) 22:2000 Sandler AB, Blumenschein GR, Henderson T, Lee J, Truong M, Kim E, Mass B, Garcia B, Johnson DH, Herbst RS (2004) Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. J Clin Oncol (Meeting Abstracts) 22:2000
45.
Zurück zum Zitat Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98 Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98
46.
Zurück zum Zitat Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ (2003) A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 9:1639–1647 Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ (2003) A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 9:1639–1647
47.
Zurück zum Zitat Sette A, Fikes J (2003) Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15:461–470 Sette A, Fikes J (2003) Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15:461–470
48.
Zurück zum Zitat Sienel W, Varwerk C, Linder A, Kaiser D, Teschner M, Delire M, Stamatis G, Passlick B (2004) Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg 25:131–134 Sienel W, Varwerk C, Linder A, Kaiser D, Teschner M, Delire M, Stamatis G, Passlick B (2004) Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg 25:131–134
49.
Zurück zum Zitat Squiban P, Velu T, Mennecier B, Pless M, Morel V, Levy E, Richard V, Maciejewska T, Bizouarne N, Quoix E (2004) MVA-MUC1-IL2 vaccine immunotherapy for advanced non small cell lung cancer (NSCLC): Interim phase II data. J Clin Oncol (Meeting Abstracts) 22:2544 Squiban P, Velu T, Mennecier B, Pless M, Morel V, Levy E, Richard V, Maciejewska T, Bizouarne N, Quoix E (2004) MVA-MUC1-IL2 vaccine immunotherapy for advanced non small cell lung cancer (NSCLC): Interim phase II data. J Clin Oncol (Meeting Abstracts) 22:2544
50.
Zurück zum Zitat Sridhar SS, Seymour L, Shepherd FA (2003) Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4:397–406 Sridhar SS, Seymour L, Shepherd FA (2003) Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4:397–406
51.
Zurück zum Zitat Stratton MR, Futreal PA (2004) Cancer: understanding the target. Nature 430:30 Stratton MR, Futreal PA (2004) Cancer: understanding the target. Nature 430:30
52.
Zurück zum Zitat Talor E, Timar J, Repassy G, Szabo G, Remenar E, Balatoni Z, Zemplen B (2004) Leukocyte interleukin, injection (LI) treatment in advanced primary squamous cell carcinoma of the head & neck a phase II multi-center trial and pathology study. J Clin Oncol (Meeting Abstracts) 22:2605 Talor E, Timar J, Repassy G, Szabo G, Remenar E, Balatoni Z, Zemplen B (2004) Leukocyte interleukin, injection (LI) treatment in advanced primary squamous cell carcinoma of the head & neck a phase II multi-center trial and pathology study. J Clin Oncol (Meeting Abstracts) 22:2605
53.
Zurück zum Zitat Tanovic A, Alfaro V (2004) Gefitinib: current status in the treatment of non-small cell lung cancer. Drugs Today (Barc) 40:809–827 Tanovic A, Alfaro V (2004) Gefitinib: current status in the treatment of non-small cell lung cancer. Drugs Today (Barc) 40:809–827
54.
Zurück zum Zitat Tolcher AW, Mita M, Patnaik A, Rowinsky EK, Corey A, Fleming M, Fox NL, Weiner LM, Meropol NJ, Cohen R (2004) A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 22:3060 Tolcher AW, Mita M, Patnaik A, Rowinsky EK, Corey A, Fleming M, Fox NL, Weiner LM, Meropol NJ, Cohen R (2004) A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 22:3060
55.
Zurück zum Zitat Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Bessa EH, Baselga J, Vermorken JB (2004) Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. J Clin Oncol (Meeting Abstracts) 22:5502 Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Bessa EH, Baselga J, Vermorken JB (2004) Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. J Clin Oncol (Meeting Abstracts) 22:5502
56.
Zurück zum Zitat Wakelee H, Kelly K (2004) Novel approaches for the treatment of small cell lung cancer. Hematol Oncol Clin North Am 18:499–518 Wakelee H, Kelly K (2004) Novel approaches for the treatment of small cell lung cancer. Hematol Oncol Clin North Am 18:499–518
57.
Zurück zum Zitat Weiner LM, Carter P (2003) The rollercoaster ride to anti-cancer antibodies. Nat Biotechnol 21:510–511 Weiner LM, Carter P (2003) The rollercoaster ride to anti-cancer antibodies. Nat Biotechnol 21:510–511
63.
Zurück zum Zitat Zwick E, Bange J, Ullrich A (2002) Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 8:17–23 Zwick E, Bange J, Ullrich A (2002) Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 8:17–23
Metadaten
Titel
Moderne immuntherapeutische Ansätze für die Behandlung von Lungen- und Kopf-Hals-Tumoren
verfasst von
PD Dr. F. Lohr
A. Dietz
A. Hoos
Publikationsdatum
01.05.2005
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 5/2005
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-005-0868-7

Weitere Artikel der Ausgabe 5/2005

Der Onkologe 5/2005 Zur Ausgabe

Weiterbildung · Zertifizierte Fortbildung

Nierenzellkarzinom

Onkologie im Internet

Webadressen zur Immuntherapie

Neu im Fachgebiet Onkologie

Mit dem Alkoholentzug sinkt das Krebsrisiko

Wie die Ergebnisse einer Studie aus Frankreich nahelegen, kann sich das Risiko von alkoholabhängigen Menschen, an einem alkoholassoziierten Tumor zu erkranken, um rund 40% vermindern, wenn sie das Trinken reduzieren oder ganz einstellen.

Gemischte Befunde zur zielgerichteten Adjuvanz

23.07.2024 Melanom Nachrichten

Mit Blick auf rezidiv- und metastasenfreies Überleben bestätigen die finalen Ergebnisse der COMBI-AD-Studie die Wirksamkeit von Dabrafenib/Trametinib beim Stadium-III-Melanom. Die Effekte auf das Gesamtüberleben sind dagegen weniger klar.  

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.